Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life. We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical pra...

Detaylı Bibliyografya
Asıl Yazarlar:	Travis, S, Feagan, B, Peyrin-Biroulet, L, Panaccione, R, Danese, S, Lazar, A, Robinson, A, Thakkar, R, Pappalardo, B, Petersson, J, Bereswill, M, Chen, N, Skup, M
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	Oxford University Press 2017

Benzer Materyaller

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results From InspirADA.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
Yazar:: Sandborn, W, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Does it all ADA up? Adalimumab for ulcerative colitis.
Yazar:: Travis, S
Baskı/Yayın Bilgisi: (2011)

Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
Yazar:: Walsh, A, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
Yazar:: Napolitano M, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis
Yazar:: Renata de Medeiros Dutra, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
Yazar:: David T. Rubin, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Raising the bar in ulcerative colitis management
Yazar:: Fabrizio Fanizzi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Pulmonary Extraintestinal Manifestation of Crohn’s Disease Treated Successfully with Adalimumab
Yazar:: Dongyeol Shin, ve diğerleri
Baskı/Yayın Bilgisi: (2018-09-01)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
Yazar:: Ferdinando D’Amico, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

A Case of Syrian Child with Cerebral Infarction as an Extraintestinal Manifestation of Ulcerative Colitis
Yazar:: Riham Salloum, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
Yazar:: Yiyoung Kwon, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Meta‐analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis
Yazar:: K. Hata, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis
Yazar:: Francesca Bernardi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Multiple extraintestinal manifestations in a patient with acute severe ulcerative colitis: a case report
Yazar:: Eun Young Park, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country
Yazar:: Jesús K. Yamamoto-Furusho, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
Yazar:: Eun Soo Kim
Baskı/Yayın Bilgisi: (2021-03-01)

Febrile neutropenia associated with adalimumab in a patient with ulcerative colitis
Yazar:: Ma’In Atallah Mohammad Abumuhfouz, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Albumin change predicts failure in ulcerative colitis treated with adalimumab
Yazar:: Natsuki Ishida, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
Yazar:: Laurel L. Wessman, BS, ve diğerleri
Baskı/Yayın Bilgisi: (2017-07-01)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Yazar:: Assasi Nazila, ve diğerleri
Baskı/Yayın Bilgisi: (2009-12-01)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
Yazar:: Armuzzi A, ve diğerleri
Baskı/Yayın Bilgisi: (2013-04-01)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
Yazar:: Freeman HJ
Baskı/Yayın Bilgisi: (2013-11-01)

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
Yazar:: Zhdanava M, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
Yazar:: Vuitton, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
Baskı/Yayın Bilgisi: (2016-03-01)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
Yazar:: Sebastian Hoffmann, ve diğerleri
Baskı/Yayın Bilgisi: (2018-05-01)

ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY
Yazar:: Patrícia ZACHARIAS, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

Leukocytoclastic Vasculitis as a Rare Dermatologic Extraintestinal Manifestation of Ulcerative Colitis in an Elderly Patient with Positive PR3-ANCA
Yazar:: Jacky Ng, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Exploring genetic associations of Crohn’s disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations
Yazar:: Chengdong Yu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
Yazar:: Shinji Okabayashi, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
Yazar:: Muhammed B. Durak, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
Yazar:: Bénédicte Caron, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature
Yazar:: Joseph J. LaConti, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
Yazar:: Saleh Azadbakht, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
Yazar:: Candace L. Beilman, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
Yazar:: Martin Wasserbauer, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)